FDA Presents Potential Framework For CBD, From Edibles To Delta-8, Reaffirms Congress Is In Charge
Portfolio Pulse from Nina Zdinjak
The FDA held a virtual panel discussing a potential framework for regulating CBD and hemp-derived products, reaffirming that Congress is in charge. The panel addressed the challenges of regulating CBD and the FDA's intention to work on a harm reduction approach. The legal status of hemp and the approval of Jazz Pharmaceuticals' Epidiolex add complexity to the regulation of CBD products.
May 30, 2023 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The FDA's potential framework for regulating CBD and hemp-derived products may impact Jazz Pharmaceuticals, as their CBD-based drug Epidiolex adds complexity to the regulation of CBD products.
The article mentions that the FDA's approval of Jazz Pharmaceuticals' Epidiolex, a CBD-based drug, makes the regulation of CBD products more complex and challenging. While the potential framework for regulating CBD and hemp-derived products is still under discussion, it may have an impact on Jazz Pharmaceuticals' business, particularly in relation to Epidiolex. However, the extent of this impact is uncertain at this stage.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50